Rabies Vaccine Market Expected to Reach $1.9 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Rabies Vaccine Market," The rabies vaccine market size was valued at $1.2 billion in 2022, and is estimated to reach $1.9 billion by 2032, growing at a CAGR of 4.7% from 2023 to 2032.

Rabies is a zoonotic viral disease that causes encephalomyelitis in almost all the warm-blooded animals including man. The causative agent is found in domestic and wild animals and is transmitted to other animals or humans through close contacts with their saliva. The saliva is transmitted through bites, scratches, licks on broken skin, and mucous membranes. Rabies vaccine is an immunization used to prevent rabies in people who have been bitten by an animal or otherwise exposed to the rabies virus. Rabies vaccine is an inactivated virus vaccine prepared either in human diploid cell culture (HDCV) or in purified chick embryo cell culture (PCEC).

The rabies vaccine market size is driven by rise in prevalence of rabies, increase in number of stray dogs in developing countries such as India, and presence of major market players who manufacture rabies vaccine. In addition, provision of high-quality vaccines by major market players is anticipated to fuel the growth of market. For instance, Sanofi S.A., a pharmaceutical company, provides Imovax rabies vaccine that is a sterile, stable, freeze-dried suspension of rabies virus, which is used as pre-exposure prophylaxis and post exposure prophylaxis. The vaccine is used for post-exposure immunization and post-exposure prophylaxis of rabies.

In addition, a rise in prevalence of rabies is anticipated to boost the growth of the market. For instance, according to report shared by Ministry of Health and Family Welfare Government of India, in 2022, it was reported that, an estimated 35172 human deaths (59.6% of global deaths) and loss of approximately 2.2 million disability adjusted life years occur per year in Asia due to dog-mediated rabies. India accounts for the most deaths in Asia (65% of human rabies deaths) and globally (36% of human rabies deaths). In addition, a rise in initiatives taken by the governments is anticipated to boost the growth of the market. For instance, in September 2023, the Tennessee Dept. of Health and the U.S. Dept. of Agriculture air drop oral rabies vaccine packets along Tennessee’s borders with Alabama, Georgia, North Carolina, and Virginia.

In addition, in September 2023, Government of India and United Nations Development Program (UNDP) partnered to strengthen rabies control program. The Centre for One Health, under the Ministry of Health and Family Welfare’s National Centre for Disease Control (NCDC), requested the support of the UNDP in India to supplement its efforts to strengthen rabies prevention and control through digitalization of rabies vaccinations. The digitalization process is expected to involve real-time monitoring of rabies vaccine stocks and tracking of beneficiaries, as well as ensure that all doses of the rabies post-exposure prophylaxis regimen are administered.

Moreover, R&D efforts have led to the creation of improved rabies vaccines, including new formulations and delivery methods. These advances make vaccination more accessible and effective. Thus, this factor is anticipated to boost the growth of the market. In addition, regulations governing pet vaccination and public health measures for rabies control drive demand for rabies vaccines within the veterinary and animal healthcare industries and foster the growth of rabies vaccine market.

However, maintaining a consistent supply of vaccines, especially in remote or resource-constrained areas, is difficult. Vaccine storage and distribution infrastructure if not adequate can lead to vaccine shortages or spoilage. Thus, this factor is expected to hinder the growth of the rabies vaccine market.

In addition, public health awareness campaigns and educational programs about rabies and the importance of vaccination have a significant impact on driving vaccine demand. These campaigns aim to inform the public about the dangers of rabies and the necessity of vaccination. Therefore, this factor provides lucrative opportunity for growth of market.

By product type, the rabies vaccine market share is classified into chick embryo cells rabies vaccine, vero cell rabies vaccine, human diploid cell vaccine and others. Others includes purified duck embryo vaccine and baby hamster kidney (BHK) cells rabies vaccine. The chick embryo cells rabies vaccine segment is expected to be the fastest growing segment during the forecast period owing to provision of vaccine by large market players and effectiveness and safety of chick embryo cells rabies vaccine. However, vero cell rabies vaccine segment is anticipated to grow during the forecast period owing to effectiveness of vaccine in pediatric patients and vaccine be use for both pre-exposure prophylaxis and post exposure prophylaxis.

By prophylaxis type, the rabies vaccine market share is categorized into pre-exposure prophylaxis and post exposure prophylaxis. The post exposure prophylaxis segment is projected to be the fastest growing segment during the forecast period owing to rise in prevalence of rabies and increase in number of exposures of human to rabies dogs or animal bites. However, pre-exposure prophylaxis segment is anticipated to grow during the forecast period owing to increase in awareness among the people regarding pre-exposure prophylaxis for rabies and provision of high-quality pre-exposure prophylaxis vaccines.

By application, the rabies vaccine market analysis is segmented into human and animal. The human segment is projected to be the fastest growing segment during the forecast period owing to increase in number of post exposure prophylaxis in human and increase in awareness among human regarding vaccination for rabies. However, animal segment is anticipated to grow during the forecast period owing to rise in number of vaccinations for pet animals and increase in number of initiatives taken by government for vaccination of animals.

By end user, the market is segregated into hospitals, veterinary clinics, and others. Others segment includes vaccine centers and specialty clinics. The hospital segment is projected to be the fastest growing segment in the rabies vaccine market trends during the forecast period owing to rise in number of post exposure prophylaxis from hospitals and availability of trained healthcare workers for consultation and health education regarding rabies in hospitals. However, others segment is anticipated to grow during the forecast period owing to rise in provision of vaccines by vaccine centers and increase in awareness among population regarding rabies.

Region-wise, North America had the highest market share in 2022 and is expected to maintain its lead during the forecast period owing to presence of large market players and highly developed healthcare infrastructure. However, Asia-Pacific is expected to exhibit fastest growth of rabies vaccine market forecast owing to high population getting exposed to bite or scratch of dogs or animals suffering from rabies and increase in awareness among people regarding vaccination.

Key Findings of the Study

• By product type, the chick embryo cells rabies vaccine segment dominated the rabies vaccine industry in 2022.
• By prophylaxis type, the post exposure prophylaxis segment dominated the rabies vaccine industry in 2022.
• By application, human segment dominated the market in 2022.
• By end user, the hospitals segment dominated the market in 2022.
• By region, North America dominated the market in 2022 and is expected to grow during the forecast period.